logo
Zookeepers in Prague turn into puppeteers to save baby vultures

Zookeepers in Prague turn into puppeteers to save baby vultures

PRAGUE (AP) — Zookeepers in Prague sometimes have to become puppeteers to save newborn birds rejected by their parents. This was the case for a lesser yellow-headed vulture chick hatched three weeks ago.
Bird keeper Antonín Vaidl said Thursday that when a dummy egg disappeared from the nest, it signaled to keepers that the parents were not ready to care for their two babies, despite doing so in 2022 and 2023.
The first-born is being kept in a box and fed using a puppet designed to mimic a parent bird, while another is expected to hatch in the next few days.
Vaidl said the puppet is needed to make sure the bird will be capable of breeding, which it won't if it gets used to human interaction.
He explained that the puppet doesn't have to be a perfect replica of an adult bird because the chick responds to certain signals, such as the pale orange coloration on its featherless head and neck.
Lesser yellow-headed vultures live in the wild in Latin America and Mexico. Prague Zoo is one of only three zoos in Europe that breed them.
In the past, the park successfully applied this treatment to save the critically endangered Javan green magpie and two rhinoceros hornbill chicks. The puppet-feeding technique is applicable for birds that live in pairs.
'The method has been working well,' Vaidl said. 'We'll see what happens with the vultures.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

"Over the moon!" — Rare and endagered Red Panda twins born at Island zoo
"Over the moon!" — Rare and endagered Red Panda twins born at Island zoo

Yahoo

time12 hours ago

  • Yahoo

"Over the moon!" — Rare and endagered Red Panda twins born at Island zoo

An Isle of Wight zoo has said it is "over the moon" following the birth of rare Red Panda twin cubs. As the mammals are an endangered species, their arrival marks a significant moment for conservation efforts. The cubs were born at Amazon Word on June 17 to mum Xaio and dad Flint. As the cubs are still young and there is always a risk, the zoo has kept the news under wraps — until now. A spokesperson said: "Xiao has done such a fantastic job so far, we are all so proud of her and Flint for helping us play our role as a vital Education and Conservation Centre.." The cubs will remain hidden in the nest boxes until at least three months old and senior staff will continue to monitor the enclosure them via CCTV. Red Pandas are native to the Eastern Himalayas and south western China and are classified as endangered on the IUCN Red List. Their population is declining due to many factors, including habitat loss, human interference and poaching. The zoo said: "Xaio and Flint are part of an International Breeding Programme with zoo's in Europe so that together we can maintain a captive population of this amazing species." "You may not be able to see the cubs at this time but we hope if you can, you'll visit us this summer."

Alnylam Pharmaceuticals, Inc. (ALNY) Gets EU Nod for AMVUTTRA
Alnylam Pharmaceuticals, Inc. (ALNY) Gets EU Nod for AMVUTTRA

Yahoo

time14 hours ago

  • Yahoo

Alnylam Pharmaceuticals, Inc. (ALNY) Gets EU Nod for AMVUTTRA

We recently compiled a list of Alnylam Pharmaceuticals, Inc. stands eighth on our list and recently got approval for AMVUTTRA. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a leading biopharmaceutical company specializing in RNA interference (RNAi) therapeutics, with four FDA-approved drugs for rare genetic diseases. Recently, the company has made significant strides in treating transthyretin amyloidosis (ATTR), a progressive disease affecting the heart and nerves. In March 2025, the FDA approved AMVUTTRA (vutrisiran) to reduce cardiovascular death and hospitalizations in ATTR-CM patients, based on strong results from the HELIOS-B Phase 3 trial. The drug also received approval from the European Commission in June 2025. Long-term data (up to 42 months) continues to support its effectiveness in improving heart function and quality of life. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), considered one of the most undervalued stocks in the biotech sector, is advancing nucresiran (ALN-TTRsc04), a next-gen RNAi treatment for ATTR. Interim Phase 1 results show sustained TTR protein reduction (over 90% within 15 days), with potential for once- or twice-yearly dosing. The drug enters Phase 3 trials in 2025 through the TRITON-CM program, aiming for longer-lasting, more convenient treatment options. A close-up of a staff member counting pills in a pharmaceutical warehouse. Beyond ATTR, the business is expanding its pipeline with nine new investigational therapies by the end of 2025, including treatments for Huntington's disease, bleeding disorders, and type 2 diabetes. The company also initiated a landmark Phase 1 trial for ALN-HTT02 in Huntington's, marking its entry into neurotherapeutics. Platform upgrades are targeting improved delivery to organs like the brain, heart, and kidneys, enhancing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)'s ability to address both rare and common diseases. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store